Methods and compositions targeting glucocorticoid signaling for modulating immune responses
AssigneesThe Broad Institute, Inc., Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
InventorsAna Carrizosa Anderson, Asaf Madi, Nandini Acharya, Vijay K. Kuchroo, Aviv Regev
Life of this patent
Estimating the term…
Abstract
The subject matter disclosed herein is generally directed to modulating T cell dysfunctional and effector states by modulating glucocorticoid and IL-27 signaling. The invention further relates to modulating immune states, such as CD8 T cell immune states, in vivo, ex vivo and in vitro. The invention further relates to diagnostic and screening methods.
Claims12
A method of treating melanoma by reducing T cell dysfunction in a subject in need thereof comprising:
- administering to the subject one or more doses of metyrapone capable of reducing glucocorticoid signaling in the tumor microenvironment,
- wherein a dysfunctional immune state in the subject is decreased when glucocorticoid signaling is reduced,
- whereby a tumor specific immune response is enhanced.
A method of treating colon cancer by reducing T cell dysfunction in a subject in need thereof comprising:
- administering to the subject one or more doses of metyrapone capable of reducing glucocorticoid signaling in the tumor microenvironment,
- wherein a dysfunctional immune state in the subject is decreased when glucocorticoid signaling is reduced,
- whereby a tumor specific immune response is enhanced.
A method of treating stomach cancer by reducing T cell dysfunction in a subject in need thereof comprising:
- administering to the subject one or more doses of metyrapone capable of reducing glucocorticoid signaling in the tumor microenvironment,
- wherein a dysfunctional immune state in the subject is decreased when glucocorticoid signaling is reduced,
- whereby a tumor specific immune response is enhanced.
Dependencies are inferred from the claim text.